Abstract:
본발명은방사성또는비방사성키토산-킬레이터하이드로겔및 이의제조방법, 및이를유효성분으로함유하는암 치료용및 색전치료용조성물에관한것이다. 본발명에따른 100 내지 300 ㎛크기로제조된키토산-킬레이터하이드로겔은종양조직으로향하는혈액의흐름을막아종양세포로의산소와영양분공급을차단함으로써암 조직에대한색전치료를위해사용될수 있으며, 특히방사성핵종이표지된키토산-킬레이터하이드로겔은방사성핵종을직접표지하거나하이드로겔형성시약물을담지함으로써, 방사성핵종의표지효율및 표지안정성이우수하여유리방사성핵종을최소화할수 있고, 방사성핵종에의한치료효과뿐만아니라약물에의한치료효과를동시에기대할수 있어병소의치료효과를높일수 있다.
Abstract:
The present invention relates to radioisotope-labeled and angiogenesis-promoting protein or peptide-loaded polymeric hydrogel, method for preparing the same, and pharmaceutical composition for preventing or treating ischemic disease comprising same as an active ingredient. The polymeric hydrogel according to the present invention directly labels radionuclides on biodegradable polymers and deposits angiogenesis-promoting protein or peptide when forming hydrogel, thereby angiogenesis-promoting protein or peptide is gradually released while staying in disease region in which polymeric hydrogel is accumulated. Therefore, waste of large amount of angiogenesis-promoting protein or peptide can be prevented; particle amount staying in ischemic diseases region can be quantified by checking bio-distribution using a gamma camera; and therapeutic effects can be predicted. In addition, the present invention releases radiation from disease region, thereby being suitably used for treating diseases such as ischemic disease. Therefore, the polymeric hydrogel according to the present invention can expect therapeutic effects by radionuclides and angiogenesis-promoting protein or peptide at the same time, and enhance therapeutic effects of disease region by quantitatively evaluating accumulation of medicines.
Abstract:
The present invention relates to a manufacturing method for quantum dots comprising: a step of manufacturing a quantum dot nanoparticle solution; a step of adding surface modification materials in the quantum dot nanoparticle solution; a step of adding water the quantum dot nanoparticle solution added with the surface modification materials and separating a water layer from a reaction solution added with the water; a step of manufacturing quantum dot nanoparticles coated with cysteamine including a process of obtaining the quantum dot nanoparticles coated with cysteamine by drying the obtained water layer after obtaining the water layer separated from the reaction solution; and a step of inducing one water-soluble monosaccharide selected from the group consisting of gluconic acid, citric acid, propionic acid, butyric acid and oleic acid.
Abstract:
본 발명은 피오글리타존을 이용한 F-18 FDG 양전자방출단층촬영에서 악성 종양과 염증 병변을 구분하여 악성 종양을 선택적으로 진단하는 방법에 관한 것으로, 상세하게는 F-18 FDG 양전자방출단층촬영에서 피오글리타존을 처리한 경우 피오글리타존을 처리하지 않은 경우에 비해 악성 종양 병변에서만 F-18 FDG의 섭취량을 증가시키고, 염증 병변에서는 F-18 FDG의 섭취량을 약간 증가시키거나 감소시킴으로써, 양전자방출단층촬영 영상 진단 시 악성 종양과 염증을 구분하여 악성 종양 병변만 선택적으로 진단하는 것을 특징으로 한다.
Abstract:
PURPOSE: An iron oxide nano particle in which non-polymer bio molecules are introduced to a surface modifier and a cancer diagnosis and treatment composition including thereof are provided to improve delivery of oxide nano particles to target organ. CONSTITUTION: An iron oxide nano particle comprises iron oxide based core particles, a shell coated with soluble material which is selected from ATP, NAD, ADP, AMP and NADP, and gluconic acid combined in surface of the shell. The soluble are ATP. Fluorescent probes are additionally combined with surfaces of the nano particles. The fluorescence probes are chlorotoxin. A weight ratio of the gluconic acid to the iron oxide based core particle which is coated with ATP is 1:0.3-1:3. A diameter of the nano particle is 5-300 nano meters.